Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $93,685.76 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 73,192 shares of the firm’s stock in a transaction dated Friday, October 31st. The stock was sold at an average price of $1.28, for a total transaction of $93,685.76. Following the sale, the director owned 4,003,728 shares of the company’s stock, valued at approximately $5,124,771.84. The trade was a 1.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Monday, November 3rd, Luke Evnin sold 60,369 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total transaction of $77,876.01.
• On Thursday, October 30th, Luke Evnin sold 55,795 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.43, for a total transaction of $79,786.85.
• On Wednesday, October 29th, Luke Evnin sold 86,154 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total transaction of $133,538.70.
• On Tuesday, October 28th, Luke Evnin sold 44,327 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.64, for a total transaction of $72,696.28.
• On Monday, October 27th, Luke Evnin sold 46,664 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.72, for a total transaction of $80,262.08.

Werewolf Therapeutics Price Performance

Werewolf Therapeutics stock opened at $1.22 on Thursday. Werewolf Therapeutics, Inc. has a 12-month low of $0.60 and a 12-month high of $2.52. The stock has a market cap of $55.79 million, a P/E ratio of -0.75 and a beta of 0.72. The company has a 50-day moving average price of $1.61 and a 200 day moving average price of $1.32. The company has a current ratio of 5.30, a quick ratio of 5.30 and a debt-to-equity ratio of 0.60.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.03. Sell-side analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on HOWL. Citigroup reiterated a “buy” rating on shares of Werewolf Therapeutics in a research report on Monday, August 25th. JMP Securities dropped their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Zacks Research upgraded shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. Bank of America dropped their price target on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, August 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $8.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Quadrature Capital Ltd acquired a new position in shares of Werewolf Therapeutics in the second quarter valued at approximately $28,000. Vontobel Holding Ltd. acquired a new position in shares of Werewolf Therapeutics in the first quarter valued at approximately $34,000. Qube Research & Technologies Ltd acquired a new position in shares of Werewolf Therapeutics in the second quarter valued at approximately $48,000. Nuveen LLC acquired a new position in shares of Werewolf Therapeutics in the first quarter valued at approximately $71,000. Finally, AQR Capital Management LLC acquired a new position in shares of Werewolf Therapeutics in the first quarter valued at approximately $79,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.